SCHEMBL637276

SCHEMBL637276

CS(=O)(=O)N1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.81
ERBB2 P04626 4/20 0.81
HPGD P15428 1/20 0.81
HTT P42858 1/20 0.81
MAPT P10636 1/20 0.54
CSNK2A1 P68400 1/20 0.51
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
BCL6 P41182 2/20 0.49
CDK2 P24941 6/20 0.47
CDK1 P06493 5/20 0.47
CDK4 P11802 3/20 0.47
CCND1 P24385 3/20 0.47
CCNE1 P24864 4/20 0.46
CCNT1 O60563 1/20 0.46
CCND3 P30281 1/20 0.46
CDK9 P50750 1/20 0.46
CDK6 Q00534 1/20 0.46
CCNB2 O95067 3/20 0.46
CCNE2 O96020 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8314537 0.95 EGFR (0.75) EGFRERBB2HPGDHTTMAPT
SCHEMBL8318350 0.90 EGFR (0.71) EGFRERBB2HPGDHTTMAPT
Falnidamol SCHEMBL29387986 0.89 EGFR (1.00) EGFRERBB2HPGDHTTMAPT
Falnidamol SCHEMBL158563 0.89 EGFR (1.00) EGFRERBB2HPGDHTTMAPT
Falnidamol SCHEMBL29403789 0.89 EGFR (0.98) EGFRERBB2HPGDHTTMAPT
Falnidamol SCHEMBL29409569 0.89 EGFR (0.98) EGFRERBB2HPGDHTTMAPT
SCHEMBL8314263 0.88 EGFR (0.84) EGFRERBB2HPGDHTTMAPT
SCHEMBL8312687 0.88 EGFR (0.75) EGFRERBB2HPGDHTTMAPT
SCHEMBL8312684 0.88 EGFR (0.75) EGFRERBB2HPGDHTTMAPT
SCHEMBL8487889 0.86 EGFR (0.70) EGFRERBB2HPGDHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419110-A1 METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES Enzon Pharmaceuticals, Inc. (US) 2012-02-22 EP disclosed
WO-2010120861-A1 METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES ENZON PHARMACEUTICALS, INC. (US) 2010-10-21 WO disclosed